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Abstract The immunophenotypic predictive profile of
BRCA1-associated cancers including major predictive
markers, i.e., PARP-1, EGFR, c-kit, HER-2, and steroid
hormones (ER/PR) that may have therapeutic relevance has
not yet been reported in a comprehensive study. Using
immunohistochemistry, we examined the expression of
these proteins in a large cohort of BRCA1-associated breast
cancers. PARP-1 immunoreactivity was found in 81.9%,
EGFR in 43.6%, ER/PR in 17.9%, c-kit in 14.7%, and
overexpression of HER-2 in 3.6% of cancers. For all
markers studied, 8.2% of tumors were negative. Expression
of only one predictive marker was found in 29.7% of
cancers, and most frequently, it was PARP-1 (20.8%). In
62.1% of tumors, more than one predictive marker was
expressed: PARP-1 and EGFR in 30.4%, PARP-1, and
hormone receptors in 13.3% and PARP-1 with c-kit in 7.5%
of all tumors. Coexpression of two or more other predictive
markers was rare. There were significant differences in the
median age at diagnosis of BRCA1-associated cancer
between patients with ER+ vs. ER− and grades 1–2 vs.
grade 3 tumors. These results demonstrate that BRCA1-
associated cancers differ with respect to expression of
proteins that are regarded as targets for specific therapies
and that 92% of patients with BRCA1-associated cancers
may benefit from one or several options for specific
therapy (in addition to DNA damaging agents, e.g.,
cisplatin). About 8% of cancers which do not express
therapeutic target proteins may not respond to such
therapies. Knowledge of the immunophenotypic predictive
profile may help with the recruitment of patients for trials
of targeted therapies.
Keywords Breast cancer.BRCA1.Estrogen receptor.
PARP-1.EGFR.c-kit
Introduction
Mutations in either of the two breast cancer susceptibility
genes BRCA1 and BRCA2 account for 2–3% of all breast
cancers, and they confer a lifetime risk of breast cancer of
60–85% [1]. BRCA1 is essential for the repair of DNA
double-strand breaks through the process of homologous
recombination. In the absence of functional BRCA1, DNA
defects may either be repaired by other mechanisms that
are error-prone or may remain unrepaired. Such BRCA
dysfunction constitutes the basis of some new targeted
therapeutic strategies [2, 3].
With a better understanding of the molecular pathways
that control cancer development and progression, new
therapeutic agents designed to target specific breast cancer
populations, such as poly(ADP-ribose)polymerase-1
(PARP-1) inhibitors, epidermal growth factor receptor
(EGFR) antagonists, or transmembrane tyrosine kinase c-
kit (CD117) inhibitors, are being tested in patients with
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associated cancer [3, 4]. However, despite the significant
progress that has been made, a variable percentage of
patients have been resistant to such therapies. One possible
reason may be that resistant tumors lack the expression of
proteins that serve as targets for such specific therapies. In
this context, we studied in this report immunohistochemical
expression of PARP-1, EGFR, estrogen receptor (ER),
progesterone receptor (PR), c-kit, and HER-2 in tissue
microarrays of a large series of BRCA1-associated breast
carcinomas in order to reveal subpopulations of BRCA1-
associated cancers that exhibit predictive immunopheno-
types, i.e., cancers that could respond to specific targeted
therapies. The expression of common predictive markers
such as ER, PR, HER-2, and EGFR has been reported in
series of BRCA1-associated breast carcinomas [5–9];
however, a comprehensive study including these proteins
with PARP-1 and c-kit has not been published.
Materials and methods
Patients This study included 140 consecutive breast cancer
patients with BRCA1 mutations (median age, 46.0 years;
range, 23–71 years) diagnosed at the West Pomeranian
Oncology Center in Szczecin (from 1996 to 2009) and at
the Regional Oncology Hospital in Olsztyn (from 1997 to
2007). Patients did not receive endocrine therapy, chemo-
therapy, or radiotherapy before surgery. All cases were
unselected for family history. The study was approved by
the local ethics committee.
Genotyping Patients were invited to participate either
during hospital stays or through mailed invitations. During
the interview, the goals of the study were explained,
informed consent was obtained, genetic counseling was
given, and a blood sample was taken for DNA analysis.
BRCA1 genetic testing was conducted at the Department of
Genetics and Pathology, Pomeranian Medical University,
Szczecin. Genomic DNA was prepared from 5–10 ml of
peripheral blood. Mutation analysis for the common Polish
mutations was performed as described previously [10]. In
brief, there are three common founder mutations in BRCA1
in Poland. The 4153delA and 5382insC mutations were
detected using a multiplex-specific polymerase chain
reaction (PCR) assay. The third mutation (C61G) generates
a novel restriction enzyme site in exon 5. This mutation is
detected after digesting amplified DNA with AvaII restric-
tion enzyme. To visualize the different BRCA1 alleles, the
PCR products were subjected to electrophoresis in a 1.5%
agarose gel and stained with ethidium bromide. To avoid
false results in all reactions, positive and negative controls
(without DNA) were used. DNA testing results indicating
the presence of mutations were confirmed by sequencing of
material from a second blood sample obtained on a
different day.
Tumor pathology Pathology review was conducted at the
Department of Pathology, Pomeranian Medical University
in Szczecin by two pathologists (PD and TH) associated
with the study. In cases where there was disagreement,
consensus was reached by consultation with a third
reviewer (WD). Only first primary invasive breast cancers
were included. Representative histological slides organized
according to an assigned random number were evaluated to
confirm the diagnosis of breast cancer type and classified
according to the Elston–Ellis histological grade [11].
Tissue microarray construction We collected all available
paraffin blocks containing enough tumor tissue from
primary breast cancers. Two different regions of tumors in
the area of the outer invasive margin of cancer were
identified and marked on hematoxylin and eosin-stained
sections. Sections were matched to their corresponding wax
blocks (the donor blocks), and two 0.6-mm-diameter cores
of the tumor were removed from these donor blocks and
inserted into the recipient master block using a tissue
microarrayer (Beecher Instruments, Silver Spring, MD).
The recipient block was cut, and sections were transferred
onto adhesive slides.
Immunohistochemistry and fluorescent in situ hybridization
Slides were deparaffinized, rehydrated, and immersed in
antigen retrieval buffer at pH 6.0 (PARP-1 and c-kit) or
pH 9.0 (ER and PR). Heat-induced antigen retrieval was
performed in a water bath at 98°C for 20 min (PARP-1) or a
pressure cooker at 120°C for 3 min (ER, PR, and c-kit). The
following monoclonal antibodies were used: anti-PARP-1
(clone F-2, dilution 1:500; Santa Cruz Biotechnology, Santa
Cruz, CA), anti-estrogen receptor (clone 1D5, dilution 1:50;
Dako, Glostrup, Denmark), and anti-progesterone receptor
(clone PgR 636, dilution 1:50; Dako). We performed
preliminary experiments with breast cancer tissue microarray
to determine the optimal PARP-1 antibody dilutions which
would give the strongest nuclear-specific staining with
minimal background. Of several dilutions tested, the dilution
1:500 proved to be the best. Expression of HER-2 and c-kit
was tested using the HercepTest kit (Dako) and c-kit
pharmDx kit (Dako), respectively, according to the manu-
facturer’si n s t r u c t i o n s . EGFR staining was performed using
the EGFR pharmDx kit (Dako) with incubation with
proteinase K for 5 min for enzymatic antigen retrieval.
Slides were incubated with the primary antibodies for 30 min
at room temperature and immunostained using the EnVision+
kit (Dako). The reaction was developed with a diaminobenzi-
dine substrate–chromogen solution, and slides were counter-
56 Virchows Arch (2011) 458:55–64stained with hematoxylin. Appropriate positive and negative
controls were included. Normal mouse immunoglobulins
were substituted for primary antibody as negative controls.
Sections of pharyngeal tonsil served as external positive
controls for PARP-1. Strong PARP-1 immunostaining was
seen in the tonsil’s lymphocytes. PARP-1-positive stromal
lymphocytes in breast cancers served as additional built-in
positive control. Cases with HER-2 staining of 2+ were
further evaluated by fluorescent in situ hybridization for
HER-2 gene amplification. In this assay, slides were
hybridized with probes to LSI HER-2/neu and CEP17
with the PathVysion HER-2 DNA Probe Kit (Abbott
Laboratories, Abbott Park, IL) according to the manufac-
turer’s instructions. Fluorescent in situ hybridization with
an amplification ratio >2.2 was considered positive.
Immunohistochemistry scoring Tumor cores were indepen-
dently assessed by two observers (PD and WD) who were
blinded to mutation status and clinicopathological data. In
cases of disagreement, the result was reached by consensus.
Tumors with lost cores or insufficient tumor tissue in the
cores were excluded from the analysis. Of the three most
frequently applied scoring systems (intensity score, pattern
score, or both combined), we used the multiplicative
quickscore method because it seemed to be the most
reliable and proved to be useful and reproducible [12].
This system accounts for both the intensity and the extent
of cell staining. Briefly, the proportion of positive cells was
estimated and given a score on a scale from 1 to 6 (1=1%
to 4%, 2=5% to 19%, 3=20% to 39%, 4=40% to 59%, 5=
60% to 79%, and 6=80% to 100%). The average intensity
of the positively staining of cells was given a score from 0
to 3 (0=no staining, 1=weak, 2=intermediate, and 3=
strong staining). A final score was then calculated by
multiplying the percentage score by the intensity score, to
yield a minimum value of zero and a maximum value of 18.
Based on the final score, nuclear PARP-1 expression was
graded as low (0–9, further referred as negative) or high
(10–18, further referred as positive). Tumors were consid-
ered as HER-2 positive if scored as 3+ or 2+ with
amplification tested by FISH [13]. ER and PR were
considered positive if staining was detected in ≥1% of
nuclei [14]. There are no commonly accepted cut-off points
reported for EGFR and c-kit. For scoring of samples stained
with EGFR, only unequivocally membranous staining in
≥1% of tumor cells was applied to define protein positivity
according to the Dako criteria in the pharmDx kit
instructions. For c-kit cytoplasmic and/or membranous
staining, ≥10% of tumor cells was counted as positive [15].
Statistics Analysis of differences in distributions of study
markers expression between the two groups of patients
was performed using the Mann–Whitney U test, and
differences between more than two groups were evaluated
by the Kruskal–Wallis test. The chi-square contingency
test for categorical variables was used to determine
differences between groups. Spearman’s nonparametric
correlation test was used for correlative analysis. All
reported p values were two sided. For all statistical
analyses, a p value <0.05 was considered significant.
Statistical analyses were performed using GraphPad Prism
5.0 software (San Diego, CA).
Results
Table 1 lists the clinicopathological details of 140 tumors
and patients with BRCA1 mutations. PARP-1 immunoreac-
tivity (Fig. 1a, b) was found in 81.9% of cancers, EGFR
overexpression (Fig. 1e, f) in 43.6%, hormone receptor
(ER/PR) immunoreactivity in 17.9%, c-kit (Fig. 1g, h)i n
14.7%, and overexpression of HER-2 in only 3.6% of
cancers (Table 2). Eleven (8.2%) tumors were negative for
all predictive markers studied (pentanegative). Five of the
latter were atypical medullary, four were ductal grade 3,
one was medullary, and one was metaplastic carcinoma. It
is worth noting that 18.1% of BRCA1-associated cancers
were PARP-1 negative (Fig. 1c, d; 20.7% in the triple-
negative subgroup). Of these, 44% were pentanegative.
Expression of only one predictive marker was found in
29.7% of BRCA1-associated cancers, and most frequently,
it was the expression of PARP-1 (20.8%) followed by
EGFR (6.7%). In 62.1% of tumors, more than one
predictive marker was expressed, and a coexpression of
PARP-1 and EGFR constituted 30.4% of all tumors
(Table 3). Coexpression of PARP-1 and hormone receptors
was found in 13.3% of all cancers and PARP-1 with c-kit in
7.5%. Coexpression of two or more other predictive
markers was a rare event. In one tumor, a coexpression
was seen of all markers studied with the exception of EGFR
(Table 3). There were no statistically significant differences
between thefrequencies ofBRCA1-associated breast cancers
expressing only one marker, two markers, or more than two
markers in the group of young patients (<50 years of age)
vs. older patients (p=0.89). A cumulative frequency
distribution of PARP-1, EGFR, ER, PR, and c-kit showed
that PARP-1 was the marker with the highest frequency of
tumors with very high score (Fig. 2). A statistically
significant positive correlation between the expression of
ER and PR (r=0.81, p<0.0001) and negative correlation
between the expression of ER and EGFR (r=−0.26, p=
0.002) as well as PR and EGFR (r=−0.24, p<0.005) were
found. There were significant differences in the median age
at the diagnosis of BRCA1-associated cancers between
patients with ER+ vs. ER− (p=0.01) as well as grades 1–2
vs. grade 3 tumors (p=0.02, Fig. 3). No statistically
Virchows Arch (2011) 458:55–64 57significant differences were noted for PR (p=0.14) or the
other markers studied.
Discussion
In the present study, we report a five marker immunophe-
notypic predictive profile of BRCA1-associated cancers
i n c l u d i n gP A R P - 1 ,E G F R ,c - k i t ,H E R - 2 ,a n ds t e r o i d
hormones (ER/PR). ER and PR are considered one
predictive marker because expression of either one predicts
response to hormonal therapy. Recently, it has become
obvious that classical pathologic features used to predict a
treatment response are insufficient as a predictive tool.
Patients with BRCA1-associated cancers in the same stage
of the disease may exhibit variable responses to therapy,
hence the need to explain these differences and reveal the
underlying molecular mechanisms. Although there are
several ongoing clinical trials aimed at demonstrating the
value of targeted therapies in patients with BRCA1-
associated breast cancers [2, 3], no comprehensive study
has been published examining the expression in tumor cells
of major proteins against which those therapies are directed.
Our results indicate that BRCA1-associated cancers differ
with respect to expression of major proteins that are
regarded as targets for specific therapies. A variable
percentage of BRCA1-associated cancers expressed each
one of the five major predictive markers, ranging from 82%
of PARP-1 positive cancers to only 3.6% of HER-2 positive
tumors. These findings have potential therapeutic implica-
tions. It has been recognized that cisplatin compounds may
effectively target BRCA1-associated cancers [16] because
BRCA1-deficient cells have an impaired ability to repair
DNA damage via homologous recombination [17]. Our
results indicate that in addition to cisplatin, roughly 30% of
BRCA1-associated patients may have one option of specific
targeted therapy while the remaining 62% of patients with
tumors which expressed two or more predictive markers
may have several options that should be judiciously
considered by their physicians in order to apply the most
effective treatment. Furthermore, it seems that about 82%
of patients with BRCA1-associated cancers that express
PARP-1 protein will most likely respond to PARP-1
inhibitor therapy, 44% expressing EGFR may respond to
EGFR antagonists, approximately 18% may respond to
hormone therapy, and 15% may respond to c-kit inhibitors
(e.g., imatinib), but only about 4% may respond to anti-
HER-2 therapy (e.g., trastuzumab). However, about 8%
may not respond to any of the abovementioned targeted
therapies because their tumors do not express proteins
that are therapeutic targets (pentanegative, i.e., PARP-1,
HER-2, EGFR, c-kit, and steroid hormone receptor
negative tumors).
In this report, we identified a subpopulation of BRCA1-
associated breast cancers characterized by low or null
expression of PARP-1 protein. This subpopulation has two
pathways of DNA repair inactive or severely compromised,
i.e., base excision repair pathway and homologous recom-
bination pathway. PARP-1 is a nuclear enzyme that plays
an important role in DNA damage repair through the base
excision single-strand repair pathway [18]. When PARP-1
is inhibited, homologous recombination repair is used in
response to DNA damage. However, BRCA-associated
cancers cannot use the homologous recombination path-
way; hence, PARP inhibition leads to tumor cells death.
This novel concept of treating BRCA-associated cancer by
causing so-called “synthetic lethality” [19, 20]l e dt o
clinical trials of PARP-1 inhibitors in breast cancer [3].
Several active clinical trials involve BRCA-associated or
triple-negative (ER−,P R −, HER-2−) breast carcinomas.
Table 1 Clinicopathological characteristics of 140 BRCA1-associated
breast carcinomas
Number Percentage
Age
<50 98 70.0
≥50 42 30.0
Histological type
Ductal 83 59.3
Atypical medullary 32 22.8
Medullary 17 12.1
Metaplastic 4 2.9
Other 4 2.9
Histological grade
1 2 1.5
2 11 7.8
3 127 90.7
Nodal status (n=136)
Positive 44 32.4
Negative 92 67.6
Tumor size (n=131)
≤2 58 44.3
>2 73 55.7
Bilateral
Yes 29 20.7
No 111 79.3
Triple negative
Yes 112 80.0
No 28 20.0
Mutation
5382insC 90 64.3
C61G 34 24.3
4153delA 16 11.4
58 Virchows Arch (2011) 458:55–64Fig. 1 Expression of PARP-1,
EGFR, and c-kit in representa-
tive cores of BRCA1-associated
breast carcinoma. a, c Fragment
of a tissue microarray with a two
neighboring cores from different
cancers. a PARP-1 expression in
the nuclei of cancer cells. b
Marked fragment of the core
from a at high magnification
showing PARP-1-positive
(brown) nuclei of cancer cells
and some lymphocytes. Mitosis
(arrow) with cytoplasmic
PARP-1 immunoreactivity. c
PARP-1 negative cancer. d
Marked fragment of the core
from c at high magnification
showing lack of PARP-1
immunoreactivity. e EGFR
expression. f Marked fragment
of the core from e showing
membranous EGFR staining. g
c-kit expression. h Marked
fragment of the core from g
showing cytoplasmic and
membranous expression of c-kit
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depend not only on the constitutional genetic background
(responsible for impairment of DNA repair mechanisms)
but also on the level of PARP-1 protein expression in tumor
cells. A dose-dependent clinical response to PARP inhibitor
therapy in phase 1 [21] and phase 2 [22] studies and less
abundant PARP-1 in MCF-7 cells that are resistant to
mitoxantrone and etoposide than in cells susceptible to
these drugs [23] suggest the therapeutic importance of the
level of PARP-1 expression in tumor cells. Our results
indicate that approximately 18% of BRCA1-associated
breast cancers may be refractory to PARP-1 inhibitor
therapy because of lack or low expression of PARP-1.
The results of studies on PARP
−/− mice and cell lines
indicate that they may be extremely sensitive to genotoxic
agents such as alkylating agents and γ-rays [24, 25]. This
may be especially important in treatment of pentanegative
tumors (44% of all tumors with lack or low expression of
PARP-1) because they lack protein targets for major
targeted therapies.
Our data suggest that about 55% of BRCA1-associated
cancers may not respond to anti-EGFR therapy because
they show null or very low expression of this protein.
Equally important seems to be the result indicating that the
vast majority of BRCA1-associated cancers may be rela-
tively resistant to hormonal therapy as well as to anti-c-kit
and anti-HER-2 therapies. Although one has to take into
Table 3 Number (%) of BRCA1-associated cancers with the expres-
sion of one or more or null predictive markers
Number Percentage
5-Negative 11 8.2
One marker
PARP-1+ 28 20.8
EGFR+ 9 6.7
c-kit+ 2 1.5
ER/PR+ 1 0.7
Coexpression of two markers
PARP-1+, EGFR+ 41 30.4
PARP-1+, ER/PR+ 18 13.3
PARP-1+, c-kit+ 10 7.5
PARP-1+, HER-2+ 3 2.2
EGFR+, ER/PR+ 1 0.7
EGFR+, c-kit+ 1 0.7
Coexpression of more than two markers
PARP-1+, EGFR+, c-kit+ 6 4.4
PARP-1+, EGFR+, ER/PR+ 2 1.5
PARP-1+, ER/PR+, HER-2+ 1 0.7
PARP-1+, ER/PR+, c-kit+, HER-2+ 1 0.7
Total 135 100
Fig. 3 Differences in age at diagnosis of BRCA1-associated breast
cancer patients with respect to the expression of predictive markers
and tumor grade. The differences of median age between patients with
ER+ vs. ER− as well as grades 1–2 vs. 3 are significant
Table 2 Expression of ER/PR, HER-2, EGFR, PARP-1, and c-kit in
BRCA1-associated breast carcinomas
Number
a Positive (%) Negative (%)
PARP-1 138 113 (81.9) 25 (18.1)
EGFR 140 61 (43.6) 79 (56.4)
ER and/or PR
b 140 25 (17.9) 115 (82.1)
c-kit 136 20 (14.7) 116 (85.3)
HER-2 140 5 (3.6) 135 (96.4)
aTumors with lost cores or insufficient tumor tissue in cores were excluded
from the analysis
bOnly one case was PR positive and ER negative
Fig. 2 Cumulative frequency distribution of EGFR, c-kit, PARP-1,
ER, and PR in the whole cohort. PARP-1 shows the highest frequency
of cases with very high scores
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these proteins does not necessarily reflect functional
competence, lack of their presence suggests ineffectiveness
of a particular targeted therapy, for example, ER—the target
of the first targeted therapy in breast cancer—is regarded as
one of the most important predictive markers for breast
cancers [26]. For ER-positive cancers tamoxifen is an
effective treatment regardless of the patient’s genotype [27].
Hence, adjuvant anti-estrogen therapy will likely be
ineffective in the treatment of breast cancer patients with
Table 4 ER, PR, HER-2, EGFR, c-kit, and PARP-1 immunohistochemical studies in BRCA1-associated breast carcinomas reported in the
literature and in the current study
References ER+ % (n+/n) PR+ % (n+/n) HER-2+ % (n+/n) EGFR+ % (n+/n) c-kit+ % (n+/n) PARP-1+ % (n+/n)
Johannsson et al. 1997 [32] 8 (3/38) 0 (0/21) 25 (9/36)
a –––
Lynch et al. 1998 [33] 23 (5/22) 23 (5/22) 5 (1/22)
a –––
Osin et al. 1998 [34] 12 (3/25) 4 (1/25) –– ––
Eisinger et al. 1999 [35] 11 (3/28) 18 (5/28) 7 (2/28)
a –––
Vaziri et al. 2001 [36] 41.4 (12/29) 41.4 (12/29) 9.7 (3/31)
a –––
Grushko et al. 2002 [37] 31 (8/26) – 13 (5/39) –––
Lakhani et al. 2002, 2005 [5, 6]1 0
b 21
b 3
b 67.3
b ––
b
Quenneville et al. 2002 [38] 15.4 (4/26)
c 30.8 (8/26)
c 3.1 (1/32)
a –––
Goffin et al. 2003 [39] 23 (7/30) ––– – –
Foulkes et al. 2004 [40] 23.6 (49/208)
c ––– – –
Brekelmans et al. 2006 [7] 26.4 (37/140) 30.3 (36/119) –– ––
Lubiński et al. 2006 [41] 15.5 (18/116)
d ––– – –
Oldenburg et al. 2006 [42] 14.3
e 21.4
e 3.9
e –––
van der Groep et al. 2006 [43] –– 19 (4/21) 67 (14/21) ––
Hagen et al. 2007 [44] 20 (8/40) ––
f –––
Honrado et al. 2007 [45] 28.1 (9/32) 21.2 (7/33) – 46.4 (13/28) ––
Atchley et al. 2008 [46] 30.9 (17/56) 28.9 (15/52) 2.6 (1/38)
g –––
Aaltonen et al. 2008 [47] 28.6 (14/49) 20.4 (10/49) 0 (0/35) –––
Litwiniuk et al. 2008 [48] 14.5 (7/48) 12.5 (6/48) 6.2 (3/48) –––
Collins et al. 2009 [49] –– –75 (15/20)
h ––
Evans et al. 2009 [50] 24 (22/87) – 0 (0/51) –––
Graeser et al. 2009 [8] 26.9 (158/587) 27 (159/587) –– ––
Kwong et al. 2009 [51] 48.4 (15/31)
i 36.7 (11/30)
i 31.0 (9/29)
i –––
Manié et al. 2009 [52] 35 (19/54) 32 (18/57) 0 (0/53) 62 (24/39) ––
Joosse et al. 2009 [53] 5.9 (2/34)
a 5.9 (2/34)
a 2.9 (1/34) –––
Lim et al. 2009 [31] –– – – 48.1 (13/27) –
Tung et al. 2010 [9] 33.7 (58/172)
j 34.1 (40/117)
j 3.4 (4/117) –––
Domagala et al. (current study) 17.1 (24/140) 13.6 (19/140) 3.6 (5/140) 43.6 (61/140) 14.7 (20/136) 81.9 (113/138)
Only reports based on more than 20 BRCA1-associated cancers are included
aDifferent than generally used scoring system
bThe percentage is based on numbers of scores assigned by two pathologists and not on the number of tumors examined. There were 165 tumors examined
for ER/PR and 158 for EGFR
cUsing both biochemical methods and immunohistochemistry
dEarly onset breast cancers only
eOnly percentage given
f15% (six of 40) by FISH
g12% (three of 25) by FISH
hTriple-negative BRCA1-associated cancers
iIncludes nine bilateral cancers
j16.3% measured using biochemical methods
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overexpressing breast cancers has resulted in significant
clinical benefit for those patients [29]. In a similar manner,
patients with BRCA1-associated tumors that overexpress
EGFR could potentially benefit from EGFR-targeted
therapy. However, the relationship of EGFR expression to
therapeutic response is not straightforward and has yet to be
fully investigated in breast cancer. This is due to various
mechanisms of EGFR dysregulation and several compen-
satory pathways present in tumor cells [30].
We found that 14.7% of BRCA1-associated breast
carcinomas expressed c-kit. In the only published report,
48.1% of BRCA1-associated tumors were c-kit positive
[31]. The difference may be explained by a low number of
cases (n=27), different cut-off level applied to distinguish
positive vs. negative cases (authors did not specify it) and
different antibody used. Imatinib has proven to be an
efficient anti-c-kit-targeted therapy for gastrointestinal
stromal tumors; however, little is known about the results
of such therapy in breast cancer, and nothing is known
a b o u ti ti nBRCA1-associated breast cancer, so the clinical
value of c-kit therapy in patients with c-kit positive
BRCA1-associated carcinomas has yet to be established.
Our finding that about 15% of BRCA1-associated breast
cancers express c-kit may help in the proper recruitment of
patients for future prospective clinical trials because only
those cancers may serve as a target for therapy with
imatinib.
In Table 4, the results of our study are compared with
major reports in the literature on the immunohistochemical
assessment of ER/PR, HER-2, EGFR, and c-kit in BRCA1-
associated breast carcinomas. The results concerning the
expression of steroid receptors and HER-2 confirm previ-
ous reports showing that the vast majority of BRCA1-
associated cancers are steroid receptor and HER-2 negative.
However, there are some differences, and they may be
attributed to limitations of the previous studies. The
majority of published reports (1) were based on a low
number of cancers (e.g., only two reports on HER-2
immunohistochemical expression are based on more than
100 cancers [5, 9]); (2) used data concerning ER/PR and
HER-2 only from pathology reports; (3) analyzed highly
selected cases, i.e., only familial BRCA1-associated cancers,
or early onset breast cancers, or triple-negative BRCA1-
associated cancers; (4) applied various criteria for scoring
and various immunohistochemical techniques which under-
went refinements over the years; and (5) included patients
whose cancers were diagnosed before BRCA1 testing era and
this might have selected patients with longer survival, e.g.,
with ER+ tumors. Our study is the first that is not restricted
to familial BRCA1-associated cancers but is based on a large
group of consecutive BRCA1-associated breast cancer
patients.
In conclusion, the current treatment recommendations
are similar for all patients with BRCA1-related cancers.
However, we have shown here that these cancers differ with
respect to their expression of the proteins that are regarded
as targets for specific therapies. Thus, BRCA1 mutation
carriers may have various therapeutic options available.
Therefore, we suggest that in order to reveal all therapeutic
options accessible to a particular patient, the tumor should
be tested for the expression of all five major predictive
markers. We believe that in the era of targeted therapy,
treatment regimens may become more tumor specific (i.e.,
more personalized) if the expression of major predictive
proteins in tumor cells is taken into account when making
treatment decisions about patients with BRCA1-associated
breast cancers. This data may also be useful when
recruiting patients for trials of specific targeted therapy,
for example, it seems probable that overall response rate of
patients with advanced breast cancer and germline BRCA1
or BRCA2 mutations in the phase 2 study of olaparib [22]
might have been better if tumors were tested for PARP-1
expression and only patients with PARP-1-positive cancer
were enrolled and treated. However, full screening of
BRCA1 may not be readily available in some countries
what may hamper recruitment of patients for such trials.
Clearly, further prospective studies are needed to reveal the
clinical utility of the immunophenotypic predictive profile
proposed in this report. Finally, because the majority of
BRCA1-associated breast cancers are thought to represent
the basal-like subtype, such predictive immunophenotype
may also be applicable to that subset of breast cancers.
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